Physician profile
Datwan Mathis
NPI 1346973187
$3,966.65
in general payments reported to CMS, 2019-2025
11 companies · $2,788 in 2025
The $2,788 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $257 · 2023: $253 · 2024: $669 · 2025: $2,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,709.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,011.73 | 2023-2025 | Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $1,022.18 | 2022-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $410.50 | 2024-2025 | Nuplazid |
| Alpha Cognition USA, INC. | $140.41 | 2025 | Zunveyl |
| E.R. Squibb & Sons, L.L.C. | $121.84 | 2025 | Cobenfy |
| Astrazeneca Pharmaceuticals LP | $120.01 | 2022 | |
| Smith+Nephew, INC. | $71.48 | 2022 | |
| Sk Life Science, INC. | $20.27 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.05 | 2023 | Rexulti, Nuedexta |
| Avanir Pharmaceuticals, INC. | $16.67 | 2022 | |
| Neurelis, INC. | $13.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Datwan Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.